Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment
Mavacamten (Camzyos®) is a myosin modulator which reduces the interactions between myosin and actin. These are overly activated in hypertrophic cardiomyopathy (HCM), a source of exaggerated ventricular contractility, energy loss, and impairment of diastolic function (relaxation). The Food and Drug Administration (FDA) and the European Medication Agency (EMA) approved mavacamten for the treatment of symptomatic obstructive HCM (NYHA class II or III) in adult patients in 2022 and 2023, respectively. The medication is not yet reimbursed in Belgium. As seen in its clinical development studies, mavacamten reduces the intraventricular gradient, improves functional capacity and reduces symptoms. It also seems to be an innovative alternative to septal reduction. Mavacamten is usually very well tolerated knowing that, through its mechanism of action, it causes a dose-dependent and reversible reduction in left ventricular ejection fraction, which must therefore be closely monitored. The good tolerance and the effectiveness of mavacamten seem to be maintained over time. Consequently, the recent European Society of Cardiology Updated Guidelines on cardiomyopathy (ESC 09/2023) already recommend mavacamten in the pharmacological management of obstructive HCM.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Revue medicale de Liege - 79(2024), 2 vom: 15. Feb., Seite 120-128 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Le médicament du moisMavacamten (Camzyos®) : premier inhibiteur réversible de l’ATP-ase de la myosine pour le traitement des cardiomyopathies hypertrophiques obstructives |
|---|
| Beteiligte Personen: |
Lancellotti, Patrizio [VerfasserIn] |
|---|
| Themen: |
56HH86ZVCT |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 16.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM368465292 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368465292 | ||
| 003 | DE-627 | ||
| 005 | 20240216232841.0 | ||
| 007 | tu | ||
| 008 | 240215s2024 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1296.xml |
| 035 | |a (DE-627)NLM368465292 | ||
| 035 | |a (NLM)38356430 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lancellotti, Patrizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mavacamten (Camzyos ®) |b first myosin modulator for obstructive hypertrophic cardiomyopathy treatment |
| 246 | 3 | 3 | |a Le médicament du moisMavacamten (Camzyos®) : premier inhibiteur réversible de l’ATP-ase de la myosine pour le traitement des cardiomyopathies hypertrophiques obstructives |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Mavacamten (Camzyos®) is a myosin modulator which reduces the interactions between myosin and actin. These are overly activated in hypertrophic cardiomyopathy (HCM), a source of exaggerated ventricular contractility, energy loss, and impairment of diastolic function (relaxation). The Food and Drug Administration (FDA) and the European Medication Agency (EMA) approved mavacamten for the treatment of symptomatic obstructive HCM (NYHA class II or III) in adult patients in 2022 and 2023, respectively. The medication is not yet reimbursed in Belgium. As seen in its clinical development studies, mavacamten reduces the intraventricular gradient, improves functional capacity and reduces symptoms. It also seems to be an innovative alternative to septal reduction. Mavacamten is usually very well tolerated knowing that, through its mechanism of action, it causes a dose-dependent and reversible reduction in left ventricular ejection fraction, which must therefore be closely monitored. The good tolerance and the effectiveness of mavacamten seem to be maintained over time. Consequently, the recent European Society of Cardiology Updated Guidelines on cardiomyopathy (ESC 09/2023) already recommend mavacamten in the pharmacological management of obstructive HCM | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dynamic obstruction | |
| 650 | 4 | |a Hypertrophic cardiomyopathy | |
| 650 | 4 | |a Mavacamten | |
| 650 | 4 | |a Myosin modulator | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a MYK-461 |2 NLM | |
| 650 | 7 | |a Benzylamines |2 NLM | |
| 650 | 7 | |a Myosins |2 NLM | |
| 650 | 7 | |a EC 3.6.4.1 |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 700 | 1 | |a de Marneffe, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Scheen, André |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale de Liege |d 1947 |g 79(2024), 2 vom: 15. Feb., Seite 120-128 |w (DE-627)NLM000044490 |x 0370-629X |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:120-128 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 2 |b 15 |c 02 |h 120-128 | ||